We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are OK with this.     OK  No, I would like to know more...
Home / About Novasep / Media & Events / Press releases

Press releases

CORONAVIRUS: NOVASEP PARTNERS WITH ASTRAZENECA TO PRODUCE COVID-19 OXFORD VACCINE FOR EUROPE

CORONAVIRUS: NOVASEP PARTNERS WITH ASTRAZENECA TO PRODUCE COVID-19 OXFORD VACCINE FOR EUROPE

15 Jun 2020

Novasep will produce the active substance of the vaccine in its Belgian facilities


 NOVASEP and LYSOGENE Announce their New Collaboration for Development and Production of GM1 Gangliosidosis Gene Therapy Product

NOVASEP and LYSOGENE Announce their New Collaboration for Development and Production of GM1 Gangliosidosis Gene Therapy Product

25 May 2020

This agreement covers the manufacturing of the Adeno-Associated Virus (AAV)


Update on coronavirus (2019-nCoV) situation

Update on coronavirus (2019-nCoV) situation

19 Mar 2020

In response to the rapidly developing Covid-19 epidemic, governments around the world are strengthening preventive and precautionary measures to limit the spread of the virus and protect populations.


Novasep implements new Biopharma Solutions Business Unit, led by Cédric Volanti

Novasep implements new Biopharma Solutions Business Unit, led by Cédric Volanti

03 Mar 2020

The new Biopharma Solutions Business Unit is created to support Novasep’s growth strategy, Rise-2, and includes all Novasep Belgium activities. Cédric Volanti has joined Novasep to lead this new BU and will be a member of Novasep’s Executive Committee.


Fire brought under control at our site in Chasse-sur-Rhône: no injury or damage

Fire brought under control at our site in Chasse-sur-Rhône: no injury or damage

23 Jan 2020

A fire broke out this morning around 4:20 am outside of a small production workshop at our site in Chasse-sur-Rhône.


Novasep launches oXYgene™, a fully integrated offer  for boosting viral vector production

Novasep launches oXYgene™, a fully integrated offer for boosting viral vector production

02 Dec 2019

Leveraging on its recent investments Senrise-IV and Senefill, Novasep launches a unique
2-year turnkey plant offer to accelerate commercial production of viral vectors.


Senefill, Novasep's commercial facility for aseptic filling and finishing operations, is now ready to operate.

Senefill, Novasep's commercial facility for aseptic filling and finishing operations, is now ready to operate.

01 Oct 2019

Senefill will be commissioned on October 1, 2019 and will offer Fill & Finish clinical and commercial services for biological products, from formulation to packaging.


NOVASEP and THERAVECTYS enter into a new license agreement on DNA Flap Technology for GMP Manufacturing of lentiviral vectors

NOVASEP and THERAVECTYS enter into a new license agreement on DNA Flap Technology for GMP Manufacturing of lentiviral vectors

16 Apr 2019

This agreement supports the growing demand for lentivector-based gene therapies, immunotherapies and vaccines


Novasep announces the success of its consent solicitation extending the maturity of its notes

20 Feb 2019

• All resolutions were approved by 100% of the participating Noteholders and C Warrantholders
• Noteholders representing 99.9% of total outstanding principal amount participated


Enzene Biosciences chooses Novasep BioSC® Pilot chromatography for its automated end to end continuous manufacture of mAb.

Enzene Biosciences chooses Novasep BioSC® Pilot chromatography for its automated end to end continuous manufacture of mAb.

04 Feb 2019

Novasep, a leading supplier of services and technologies for the life sciences industry, announces Enzene Biosciences (India) has chosen BioSC® Pilot for purification of biopharmaceuticals to operate in its Pune plant.



You can stay on this page and select more documents or you can directly download the brochure(s) you selected
Give us your feedback!
.